TY - JOUR T1 - The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients JF - Anticancer Research JO - Anticancer Res SP - 5703 LP - 5707 DO - 10.21873/anticanres.13769 VL - 39 IS - 10 AU - PETER GEORGAKOPOULOS AU - MICHAEL KYRIAKIDIS AU - ANASTASIA PERPINIA AU - APOSTOLOS KARAVIDAS AU - STELIOS ZIMERAS AU - NIKOLAOS MAMALIS AU - MAROUSA KOUVELA AU - ANDRIANI CHARPIDOU Y1 - 2019/10/01 UR - http://ar.iiarjournals.org/content/39/10/5703.abstract N2 - Background/Aim: Anthracyclines, such as doxorubicin, though widely used in anticancer therapy, they are associated with cardiotoxic side-effects. The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier. Patients and Methods: Overall, 147 patients were randomized into the treatment arms. A total of 125 patients treated with doxorubicin without evidence of heart disease at the start of chemotherapy were analyzed. They were followed-up for up to 10 years after treatment start. Results and Conclusion: A total of 47 patients completed the follow-up and 21 patients died, none due to cardiotoxicity events. Clinical signs of heart failure were not seen in any patients and no statistically significant differences between baseline and 10-year findings were seen for echocardiographic variables. No evidence of long-term cardiotoxicity was seen and nor metoprolol or enalapril offered an additional benefit. ER -